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ABSTRACT: Pain is a key unmet need and a
major aspect of non-motor symptoms of Parkinson’s dis-
ease (PD). No specific validated scales exist to identify
and grade the various types of pain in PD. We report an
international, cross-sectional, open, multicenter, one-
point-in-time evaluation with retest study of the first PD-
specific pain scale, the King’s PD Pain Scale. Its seven
domains include 14 items, each item scored by severity
(0-3) multiplied by frequency (0-4), resulting in a sub-
score of 0 to 12, with a total possible score range
from 0 to 168. One hundred seventy-eight PD patients
with otherwise unexplained pain (age [mean6SD],
64.38611.38 y [range, 29-85]; 62.92% male; duration of
disease, 5.406 4.93 y) and 83 nonspousal non-PD con-
trols, matched by age (64.256 11.10 y) and sex (61.45%
males) were studied. No missing data were noted, and
floor effect was observed in all domains. The difference
between mean and median King’s PD Pain Scale total
score was less than 10% of the maximum observed
value. Skewness was marginally high (1.48 for patients).
Factor analysis showed four factors in the King’s PD
Pain Scale, explaining 57% of the variance (Kaiser-
Mayer-Olkin, 0.73; sphericity test). Cronbach’s alpha was
0.78, item-total correlation mean value 0.40, and item
homogeneity 0.22. Correlation coefficients of the King’s
PD Pain Scale domains and total score with other pain
measures were high. Correlation with the Scale for Out-
comes in PD-Motor, Non-Motor Symptoms Scale total
score, and quality of life measures was high. The King’s
PD Pain Scale seems to be a reliable and valid scale for
grade rating of various types of pain in PD. VC 2015 Inter-
national Parkinson and Movement Disorder Society
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Pain is a frequent yet poorly understood non-motor
symptom (NMS) of Parkinson’s disease (PD), a key
determinant of quality of life1,2 and recognized by
James Parkinson himself.3 Pain in PD is heterogene-
ous and can be multifactorial in origin.4 Various
attempts of classification of pain exist based on cause
(nociceptive vs. neuropathic pain), origin, location,
and chronicity.4,5 Prevalence data of pain from epide-
miological studies report a wide variation, quoting
rates ranging from 30% to 83%, largely owing to the
lack of a validated instrument to assess pain in PD in
clinical practice.6 The latter issue also may explain
why pain remains undeclared in 40.5% of PD
patients when up to 80% of PD patients experience
chronic pain.4,7
In this study, we present validation data from the
first ever specific PD pain scale (King’s PD Pain Scale
[KPPS]) from a multicenter European field study.
Methods
Design
This was an international, cross-sectional, open,
multicenter, one point-in-time evaluation with re-test
study.
Patients and Consent
Parkinson’s patients satisfying the UK PD Brain
Bank criteria for diagnosis of idiopathic PD were
invited to participate after informed consent if they
had pain, as declared in item 10 of the NMS question-
naire (NMSQuest).7 Exclusion criteria comprised:
a. Alternative or uncertain diagnosis of Parkinson’s
or drug-induced Parkinsonism
b. Inability to give consent
c. Dementia (formally diagnosed following interna-
tionally accepted criteria)
d. Diagnosis of disorders causing pain unrelated to
PD (eg, severe osteoarthritis/arthritis, malignancy)
Sample Size
Prevalence of PD pain has previously been reported
as 30% to 40% of PD patients. The sample size was
calculated using baseline data from NMS Quest and
NMS Scale (NMSS) studies, which report pain in 30%
to 40% of patients (pain is a self-declaration item in
NMSQuest and rated by severity and frequency in
NMSS).7,8
Because the KPPS has 14 items, and following the
recommended subject-to-item ratio of 10:1, a mini-
mum number of 140 patients was required for the
field validation. This sample size was increased by
15% to 160 to cover for missing data, input errors,
and observer variability.
We estimated a ratio of patients to controls of 2:1.
Assessments
The KPPS is a rater-interview–based scale with the
patient (aided by the carer if needed). Item generation was
based on the advice of pain specialists, PD nurse specialists,
and clinical advice from the PD Non-Motor Group
(PDNMG) and the International Parkinson’s and Move-
ment Disorder Society (IPMDS) Non-Motor PD Study
Group. In addition, we considered more than 500 patient
responses related to pain items in NMSQuest and NMSS
as well as a specific analysis of responses in relation to
pain-related questions from a local study9 (Fig. 1). The final
structure of the scale was based on the Chaudhuri-Schapira
classification of pain in PD (used in the PANDA study,
OXN2504, ClinicalTrials.gov number NCT01439100) as
well as classifications proposed by Wasner and Deuschl,5
Negre-Pages et al.,10 Tinazzi et al.,11 and Ford.4 The struc-
ture and the content of the scale was also reviewed and
approved by an accredited Parkinson’s expert patient
group.
The final scale thus addresses localization, intensity,
and frequency of pain as well as its relationship with
motor fluctuations or musculoskeletal pain.
The KPPS has seven domains including 14 items.
Domains 1 (musculoskeletal pain) and 2 (chronic pain)
are nociceptive pain; neuropathic pain is included in
domains 2 and 6 (discoloration; edema/swelling). Addi-
tionally, the scale includes fluctuation-related pain
(domain 3), nocturnal pain (such as pain related to rest-
less legs syndrome) (domain 4), orofacial pain (domain
5), and radicular pain (domain 7). Each item is scored by
severity (0, none to 3, very severe) multiplied by fre-
quency (0, never to 4, all the time) resulting in a subscore
of 0 to12, the sum of which gives the total score with a
theoretical range from 0 to 168. This pattern has been
successfully used in various widely validated scales.8
In addition to taking medical history and completing
the KPPS, the following assessments, validated for PD,
were applied (Table 1):
 Hoehn and Yahr (HY) classification12
 Scale for Outcomes in PD-Motor (SCOPA-Motor)13,14
 Non-Motor Symptoms Scale (NMSS)8
 Clinical Impression of Severity Index in PD15
 Hospital Anxiety Depression Rating Scale (HADS)16
 EQ-5D-3L, a generic, preference-based health-
related quality of life measure17
 PDQ-8, a specific instrument for assessment of
health-related quality of life in PD18
 Parkinson’s disease sleep scale-version 2 (PDSS-2)19
 Wearing-Off Questionnare 9 (WOQ-9), recom-
mended for screening of WO in PD20
 Visual analog scales (VAS) for pain severity and
frequency21
Procedure
Patients were recruited from the Parkinson’s clinic
at the center of excellence at King’s and seven UK
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centers, and the IPMDS non-motor PD study group
network centers in Sweden, Germany, Italy, and
Romania. As in NMSS validation studies, the scales
were administered in English.8
Consecutive patients with a confirmed diagnosis of
PD (UK PD Brain Bank criteria22) were administered
the NMSQuest, and those answering “yes” to ques-
tion 10 (unexplained pain) were consented and
recruited. Patients were assessed in “on” state.
Interobserver reliability was assessed by simultaneous
and independent evaluation by two raters. Test–retest
reliability was evaluated at baseline and at follow-up
assessment 7 to 15 d later by the same rater in stable
patients (controlled by both pain VAS5baseline65%).
Non-spousal, non-PD controls were also recruited
from outpatient clinics and matched by age and sex. Con-
trol subjects underwent HADS, EQ-5D-3L, and KPPS
without the dyskinesia and motor fluctuations section.
Ethical Aspects
All participants provided informed consent. The
study was approved by the respective hospital ethical
committees/institutional review boards. In the United
Kingdom, the study was adopted by the UK national
CRN (UKCRN No 13344).
Data Analysis
Data from individual centers were collected centrally,
entered in a web-based anonymized database (National
Institute of Health Research, Biomedical Research
Centre), and transferred to the Neuroepidemiology Unit at
Carlos III Institute of Health, Madrid (Spain), for analysis.
In addition to descriptive statistics to define the sam-
ple, the following clinimetric attributes were assessed:
1. Acceptability: A 95% value of computable data
was considered acceptable.23 Fifteen percent was
accepted as maximum value for floor and ceiling
effect.24 Mean and median difference was consid-
ered acceptable at less than 10% of maximum
observed value. Limits for skewness were 21 and
11.25 Acceptability was analyzed separately for
patients and controls. Other items were deter-
mined for patients only (target population).
2. Internal consistency: Cronbach’s a coefficient, cor-
rected item the total correlation, and item homo-
geneity were determined. Criterion values were
0.7026 or higher, greater than 0.20,27 and greater
than 0.20 (for a broad construct),28 respectively.
3. Dimensionality: an exploratory factor analysis
by principal component factor method, with
FIG. 1. The King’s Parkinson’s Disease Pain Scale (KPPS).
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orthogonal rotation, was completed. Kaiser-
Mayer-Olkin measure of sampling adequacy and
Bartlett’s sphericity test were applied, and values
greater than 0.6 and P<0.05, respectively, were
considered adequate.29
4. Hypotheses testing: An a priori hypothesis was
made that KPPS scores would show close correla-
tion (rs>0.50)
30 with visual analog pain scales
and item 27 of the NMSS (convergent validity).
Moderate (rs50.35-0.50) or high correlations
were also expected with the corresponding items/
domains of SCOPA motor, WOQ-19, and PDSS-
2. Correlation between KPPS domains (internal
validity) was expected to be low or moderate,
given the diversity of pain modalities. The known
groups validity (sex, HY-based severity levels,
TABLE 2. Demographics of patients and controls
Item Patients Controls
Number 178 83
Male sexa 122 (62.92%) 51 (61.45%)
Ageb 64.386 11.38: 29-85 64.256 11.10
Educationb 14.056 3.80: 9-24 14.646 4.25
Duration of diseaseb 5.406 4.93: 0-26 N/A
HY stage 1a 38 (21.35%) N/A
HY stage 2a 85 (47.75%) N/A
HY stage 3a 42 (23.60%) N/A
HY stage 4a 12 (6.74%) N/A
HY stage 5a 1 (0.56%) N/A
Levodopa equivalent
daily dose
539.496 435.77 mg N/A
aShown as number (%).
bShown as mean6SD (years): range.
TABLE 1. Scales used in the study
Patients
Name of Scale Scale Characteristics Rater-Based Patient-Based Controls
Hoehn & Yahr staging Motor staging of PD: Original staging:
1, 2, 3, 5, and 5.
X
SCOPA-Motor scale Assessment of motor disability and complications
Item score: 0 (normal) to 3 (severe)
Total score: sum of ıtems (0-75)
X
Non-Motor Symptoms
Scale (NMSS)
Assessment of NMS over the last month:
30 items in 9 domains.
Item score: severity (0-3) multiplied by frequency (1-4).
Total score: sum of domains (0-360)
X
Clinical Impression of Severity
Index (CISI-PD)
Clinical estimate of current PD global severity
Item score: 0 (normal) to 6 (very severe)
Total score: sum of ıtems (0-24).
X
King’s PD Pain Scale (KPP) Assessing pain over the last month
14 items in 9 domains (see Fig. 1)
Item score: severity (0-3) multiplied by frequency (0-4).
Total score: sum of domains (0-168)
X X
Hospital Anxiety and Depression
Scale (HADS)
Assessing current description of feelings
14 items, 7 for anxiety and 7 for depression
Item score: 0 (best case) to 3 (worst case)
Total score: sum of ıtems (0-42)
X X
European Quality of Life-5 Dimensions-3
Levels (EQ-5D-3L)
5 items for assessment of health state today
Item score: 1 (best case) to 3 (worst case)
Total score: sum of ıtems (5-15)
X X
Parkinson’s Disease Questionnaire - 8
items (PDQ-8)
Assessment of HRQoL over the last month
8 items, each scoring 0 to 4
Total score: sum of ıtems (0-32).
PDQ-8 Summary Index: % total score of
maximum possible score
X
Parkinson’s Disease Sleep
Scale 2 (PDSS-2)
15 items assessing sleep in the last week
Item score: 0 (best case) to 4 (worst case)
Total score: sum of ıtems (0-60)
X
Wearing-Off Questionnaire - 9 items
(WOQ-9)
9 items assessing wearing off in the past month
for presence and improvement of symptom (yes/no)
Item score: 1 for “yes” or 0 for “no”
Total score: sum of ıtems (0-9)
X
Visual analogue pain scales Assessing pain over the last month
Severity (0, not at all to 100, very severe)
Frequency (0, not at all to 100, all the time)
Total score: severity multiplied by frequency
(0-10,000)
X
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EQ-5D-3L Pain categories) was explored with
the Mann-Whitney or Kruskal–Wallis test.
5. Precision of the scale was determined by means
of the standard error of measurement (SEM) on
the test–retest reliability,26 considering satisfac-
tory an SEM of less than one-third standard devi-
ation at baseline.24
6. Reliability: For both test–retest (n5 47 patients)
and inter-observer reliability (n549), item scores
reproducibility was tested with weighted kappa
index with square weights and total scores with
intraclass correlation coefficient. Values higher
than 0.70 were deemed acceptable.26,31
For comparison between patients and controls, the
Mann-Whitney test was used and corrected by
Benjamini-Hochberg method for multiple compari-
sons.32 Based on the medical history, levodopa-
equivalent daily dose was calculated according to
Tomlinson et al.33
Results
One hundred seventy-eight PD patients with other-
wise unexplained pain and 83 non-spousal non-PD
controls, matched by age, sex, and duration of educa-
tion, were studied. Demographics are shown in
Table 2; scores of applied measures in Table 3.
Differences between patients and controls for
HADS-Depression and EQ-5D-3L were significant
(P<0.0001), but not for HADS-Anxiety. The KPPS
data for both groups are shown in Table 4. Although
scores, as a whole, were higher (worse) in PD patients,
only items 1, 5, 6, 8, and 14 reached statistical signifi-
cance between groups after correction. The KPPS
TABLE 4. Scores of the King’s Parkinson’s Disease Pain Scale
Patients Controls
Items Mean SD Range Mean SD Range
1. Pain around joints (musculoskeletal)a 6.02 4.07 0-12 3.66 3.69 0-12
2. Pain deep within the body 2.13 3.76 0-12 0.83 2.24 0-12
3. Pain related to internal organ 1.24 2.82 0-12 0.54 1.73 0-9
4. Dyskinetic pain 1.24 3.05 0-12 0.25 1.29 0-8
5. “Off” dystonia in a regiona 2.42 3.90 0-12 0.18 0.83 0-6
6. Generalized “off” period paina 1.62 3.33 0-12 0.19 1.09 0-9
7. PLM or RLS-associated pain 1.60 3.08 0-12 0.61 1.85 0-9
8. Pain while turning in beda 3.32 4.08 0-12 0.88 2.16 0-9
9. Pain when chewing 0.37 1.47 0-8 0.05 0.44 0-4
10. Pain due to grinding teeth 0.34 1.58 0-12 0.05 0.35 0-3
11. Burning mouth syndrome 0.26 1.29 0-12 0.14 1.32 0-12
12. Burning pain in the limbs 1.35 3.08 0-12 0.46 1.72 0-9
13. Lower abdominal pain 0.94 2.44 0-12 0.41 1.79 0-12
14. Shooting pain/pins & needlesa 2.36 3.53 0-12 1.07 2.49 0-12
Domains
1. Musculoskeletal paina 6.02 4.07 0-12 3.66 3.69 0-12
2. Chronic paina 3.37 5.53 0-24 1.37 3.23 0-18
3. Fluctuation-related paina 5.27 8.26 0-36 0.63 2.30 0-14
4. Nocturnal paina 4.91 5.87 0-24 1.49 3.36 0-15
5. Oro-facial paina 0.97 3.00 0-22 0.24 1.42 0-12
6. Discoloration, edema/swellinga 2.29 4.49 0-24 0.87 2.66 0-15
7. Radicular paina 2.36 3.53 0-12 1.07 2.49 0-12
Total scorea 25.19 22.14 0-102 9.34 12.58 0-63
aSignificant difference between patients and controls after Benjamini-Hochberg correction for multiple comparisons (P< 0.026).
TABLE 3. Descriptive statistics of the
assessments in the study
Mean SD Range
Patients
SCOPA-Motor Scale 17.38 10.28 1-65
Non-Motor Symptoms Scale 60.71 44.31 0-235
Clinical Impression of
Severity Index
6.54 3.93 0-19
Hospital Anxiety and Depression
Scale: Anxiety
6.17 4.56 0-20
Hospital Anxiety and Depression
Scale: Depressiona
5.44 3.96 0-18
EQ-5D-3La 0.52 0.28 20.43-1
PDQ-8 27.84 20.28 0-93.75
Parkinson’s Disease Sleep Scale-2 18.25 11.20 0-51
WOQ-9—Total of fluctuating symptoms 3.15 2.62 0-9
Visual analogue pain scale—Frequency 55.57 25.27 0-100
Visual analogue pain scale—Severity 53.85 23.27 0-100
Controls
Hospital Anxiety and Depression
Scale: Anxiety
5.37 3.72 0-16
Hospital Anxiety and Depression
Scale: Depressiona
3.06 2.85 0-14
EQ-5D-3La 0.77 0.23 20.18-1
aDifference between patients and controls was significant (P< 0.0001).
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domains and total score, however, were significantly
higher in patients, although the difference in orofacial
pain domain did not reach statistical significance.
No data were missing in the KPPS. Floor effect was
observed in all domains, from 44.38% (nocturnal
pain) to 84.83% (oro-facial pain), with exception of
musculoskeletal pain (15.17%). A higher floor effect
was found for all domains in the control group. No
ceiling effect was noted for any domain in any group,
except a marginal one for item 1 in the patient group.
The KPPS total score showed negligible floor or ceiling
effects (both, 0.56%) in patients, whereas a marginal
floor effect (19.28%) was present in controls. The dif-
ference between mean and median KPPS total score
was less than 10% of the maximum observed value,
and skewness was marginally high (1.48 for patients).
Factor analysis identified four factors in the KPPS
explaining 57% of the variance (Kaiser-Mayer-Olkin,
0.73; sphericity test, P< 0.001). Factor 1,“Internal
pains”, included chronic pain, generalized abdominal
pain, and pain down the limbs items (items 2, 3, 13,
and 14); factor 2 was coincident with the domain
“fluctuation-related pain” (items 4-6); factor 3, “pain
in limbs”, included item 1 (musculoskeletal pain),
items 7 and 8 (domain “nocturnal pain”), and 12
(burning limb pain); factor 4 overlapped with “oro-
facial pain” of the KPPS.
Cronbach’s alpha was 0.78, with deletion of any
item barely modifying this value (0.75-0.79). Item-
total correlation mean value was 0.40, ranging from
0.17 (pain when chewing) to 0.54 (generalized “off”
period pain). Item homogeneity was 0.22.
Correlation coefficients of the KPPS domains and
total score with other pain measures are shown in
Table 5a. Correlations were high, with VAS total
score (rS50.55) and item 12 of the PDSS-2 (painful
posturing in early morning; rS50.58). Other correla-
tions were weak or moderate. We found a high corre-
lation between PDSS-2 item 4 and KPPS item 7
(rS5 0.54), both related to restless legs syndrome, and
between PDSS-2 item 9 and KPPS item 8 (rS50.52)
related to difficulty turning in bed. The KPPS Item 4
(dyskinetic pain) showed a high correlation (rS5 0.64)
with the dyskinesia score of SCOPA-Motor (items 18
and 19). The KPPS items 4, 5, and 6 (pain in “off”
periods) reached a moderate/high association
(rS50.43-0.44) with the fluctuations score of SCOPA-
Motor (items 20 and 21). Finally, a moderate correla-
tion (rS5 0.47) was found between KPPS total score
and number of fluctuating symptoms in the WOQ-9
and between items 5 and 6 of the KPPS (pain in “off”
periods) and the number of fluctuating symptoms in
the WOQ-9 (rS50.46).
The correlation of the KPPS total score with other
variables in the study is shown in Table 5b. The KPPS
total score was not significantly different between
sexes but significantly increased with increasing HY
TABLE 5a. Convergent validity of the King’s Parkinson’s Disease Pain Scale
Domains VAS Total NMSS Item 27 PDQ-8 Item 8
PDSS-2
Item 10 Item 11 Item 12
1. Musculoskeletal pain 0.45 0.22 0.16 0.24 0.19 0.22
2. Chronic pain 0.34 20.04* 0.17 0.27 0.25 0.34
3. Fluctuation-related pain 0.24 0.08* 0.41 0.38 0.36 0.39
4. Nocturnal pain 0.32 0.10* 0.36 0.44 0.36 0.47
5. Oro-facial pain 0.21 20.08* 0.09* 0.22 0.17 0.29
6. Discoloration, edema/swelling 0.24 20.07* 0.25 0.34 0.38 0.37
7. Radicular pain 0.23 20.04* 0.26 0.32 0.32 0.37
Total score 0.55 0.21 0.45 0.50 0.47 0.58
*Nonsignificant Spearman rank correlation coefficients. All others, P< 0.05 or lower.
VAS, visual analog scale; NMSS, non-motor symptom scale; PDQ-8, Parkinson’s disease questionnaire - 8 items; PDSS-2, Parkinson’s disease sleep scale—
version 2.
TABLE 5b. Correlation of the King’s Parkinson’s Disease
Pain Scale with other variables in the study
Spearman R P
Age 0.00 1.00
Years of education 20.19 0.01
Age at onset of PD 20.14 0.07
PD duration 0.36 <0.0001
Hoehn and Yahr staging 0.24 0.001
SCOPA-Motor Examination 0.27 0.0003
SCOPA-Motor ADLa 0.58 <0.0001
SCOPA-Motor Complications 0.49 <0.0001
SCOPA-Motor Total scorea 0.51 <0.0001
Non-Motors Symptoms Scalea 0.59 <0.0001
HADS-Anxiety 0.43 <0.0001
HADS-Depression 0.48 <0.0001
CISI-PD Total scorea 0.53 <0.0001
LEDD 0.30 <0.0001
EQ-5D-3L Summary Indexa 20.56 <0.0001
PDQ-8 Summary Indexa 0.58 <0.0001
aHigh correlation with King’s Parkinson’s Disease Pain Scale total score.
PD, Parkinson’s disease; SCOPA, Scale for Outcomes in PD; HADS, Hospital
Anxiety Depression Rating Scale; CISI-PD, Clinical Impression of Severity
Index in PD; LEDD, levodopa-equivalent daily dose; EQ-5D-3L, European
quality of life-5 dimensions-3 levels; PDQ-8, PD Questionnaire-8 items.
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stage (P5 0.003) and EQ-5D-3L item (pain/discomfort
level) (P< 0.0001).
The KPPS total score inter-rater reliability analysis
found an intraclass correlation coefficient (two-way,
random effect)5 0.99, and the test–retest (interval
between evaluations: 13.7965.65 d; one-way, ran-
dom effect)50.96.
For both reliability analyses, weighted kappa for
items ranged from 0.76 to 1.00, most of the results
being 0.90 or higher. The SEM of the KPPS total score
was 4.92 (1/3 SD at baseline: 8.21).
Discussion
We report the development of the first scale for a
global and bedside evaluation of the burden and char-
acterization of various phenotypes of pain in PD
patients. The scale is easy to administer, requiring the
investigator to ask the patient 14 questions and to
score both severity and frequency within approxi-
mately 10 to 15 minutes. Data from seven domains
provide information on different types of pain in PD,
broadly classified to nociceptive and neuropathic pat-
terns. Specifically, KPPS captures pain ranging from
wearing off related pain to central, orofacial, and
radicular pain. A total score provides the overall sum
of the burden of pain in PD similar to one obtained in
analogous scales such as PDSS-2 and NMSS.8,19
Despite the complex construct, the scale is valid and
reliable. Importantly, a high correlation exists between
KPPS score and severity of disease as well as health-
related quality of life (HrQol) in PD.
As usual in clinical samples, intermediate stages of
PD were overrepresented, although we included
patients in all stages. Importantly, the patient popula-
tion studied ranged from those “just diagnosed” to 45
years disease duration, making this a representative
sample of PD population. As such, we believe that the
applicability of the scale should be generalizable to
the broad range of patients except those with the most
severe cognitive impairment, where the scale could not
be tested. Patients were tested in “on” state as recom-
mended by the IPMDS. This is also reflected in the
fact that 65% of the population studied had motor
fluctuations (as per WOQ-9 scale assessment), thus
increasing the likelihood of report of fluctuation-
related pain.
Management of pain in PD is complicated by the
fact that there are as yet no standardized tools for a
global assessment of pain in PD, taking into account
the various types of pain as well as distinction, as far
as possible, between pain directly related to the patho-
genic process of PD and pain that arises secondary to
comorbidity of PD.5
Regarding clinimetric quality, quality of data
obtained in this study was very satisfactory with no
missing data. Acceptability parameters of the domains
showed the floor effect of diverse magnitude, as a
whole, but no ceiling effect, whereas the total score
was free of both effects. The floor effect of the
domains was a consequence of low prevalence of the
corresponding types of pain in the sample, clearly
reflected through the higher floor effect in the control
group. Other acceptability aspects showed satisfactory
results. The factorial structure was consistent with a
regional distribution of pain (factors 1, 2, and 4) or
dependence on fluctuations. This grouping of symp-
toms was partially coincident with the primary divi-
sion in domains of the scale and offers an additional
option for data analysis.
Considering the primary structure in domains of the
scale (five with one or two items) and its partial coin-
cidence with the factor analysis, internal consistency
testing showed that the corresponding parameters
were satisfactory. Because the domains were heteroge-
neous and some consisted of one or two items only,
internal consistency is reported for the whole scale
and not the individual domains.
Data on convergent validity show a satisfactory
association with a range of measures related to global
pain perception, pain-related manifestation during
sleep and fluctuations, a set of aspects very consistent
with the conceptual framework embedding pain in
PD. High correlations with motor disturbances, total
score of the NMS, Clinical Impression of Severity
Index in PD, and QoL measures provide additional
data favoring the multiple associations that pain can
settle with many other aspects of the disease and influ-
ence on HrQoL.34,35 Also, the KPPS total score
increased with increasing HY stage and categories of
the EQ-5D-3L item pain/discomfort, showing a satis-
factory discriminative validity. The scale did not show
significant sex differences, a finding contrary to other
reports.36,37
Finally, both aspects of reliability, inter-rater and
test–retest, were excellent for items and domains.
Because of the strong relationship between the SEM
and reliability, the precision of the scale was very sat-
isfactory. The quality of these properties predict an
adequate responsiveness for long-term longitudinal
observations and clinical trials.38,39
The study allows discussion regarding frequency of
occurrence and localization of the different types of
pain as detailed in the KPPS compared with an age-
matched control group. Despite excluding patients
with a clear “pain-related condition” (eg, significant
osteoarthritis), item 1 of the scale (musculoskeletal
pain) showed a significantly high mean value. This is,
however, not surprising because musculoskeletal pain
is highly prevalent in PD and may not necessarily
imply arthritis.11 The higher rate of musculoskeletal
pain in PD than controls suggests that such pain
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occurs in PD regardless of duration or severity of dis-
ease. Other significantly frequent pain in PD (com-
pared with controls) included “off related pain,”
“pain while turning in bed,” as well as “shooting
pain” and “pins and needles”. “Off”-related pain indi-
cates pain of motor fluctuations and is expected to be
present in the levodopa-treated cohort within the
patients tested with KPPS. Nighttime pain, while turn-
ing in bed, is possibly reflective of nocturnal akinesia,
a common problem in PD. Finally, shooting pain and
pins and needles represent radicular pain and could be
linked to indirectly aggravated pain or pain arising
from arthritis or joint-related problems.
Limitation of the Current Study
The KPPS is an evaluative measure for pain-related
symptoms in PD with “lumping” of various types of
pain symptoms together. However, this allows
addressing the overall burden of pain-related symp-
toms in an individual patient and also may allow iden-
tification of the subtype of pain, which may be
relevant in a patient. We excluded patients with clini-
cally relevant dementia for whom report of subjective
aspects of pain would be unreliable or impossible.
In conclusion, we present validation data for the
first PD-specific pain scale, the KPPS, based on an
international multicenter study. Despite the complex-
ity of the structure of the scale, this controlled study
provides evidence that the KPPS is a valid and reliable
scale. Further large-scale linguistic validation studies
are now needed.
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